flow trial semaglutide nejm The Big of a GLP-1 drug (Wegovy) to Reduce Major Cardiovascular Events flow trial semaglutide kidney outcomes

Examining adherence and/or discontinuation rates (side effects can cause discontinuation)

This is attributed to somatotroph desensitization and somatostatin feedback

11.2.16 Compare and evaluate nutrition assessment data against appropriate standards and norms based on the client population, setting, and goals for care

Overall, the studies showed that the drugs support vascular health, which may be especially helpful to those at risk of vascular dementia

GLP-1 receptor agonists reduce all-cause mortality and major adverse cardiovascular events (MACE) by approximately 1213% in high-risk populations, as detailed in this 2025 review of cardiovascular effects of GLP-1 receptor agonists on PubMed